secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001104659-25-075244
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma Q2 net loss $3.7M; QRX003 advances with FDA/EMA designations
-------------------------------------------------------------------------

- Net loss Q2 2025 $3.7M vs $2.0M YoY; cash $7.8M supports operations into Q1 2026.
- Positive 6-month pediatric Netherton data: skin improvement, reduced itch, no adverse events.
- FDA cleared second pivotal study (CL-QRX003-002); NDA filing targeted later 2026.
- EMA granted Orphan Drug Designation; FDA granted Rare Pediatric Disease Designation for QRX003.
- Positive 12-week Peeling Skin Syndrome data: improved disease severity and quality of life.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925075244/0001104659-25-075244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925075244/tm2522891d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer